
Keywords: Adventitious viruses; Biologics; Vaccines; Biotherapeutics; Cell substrate; Next generation sequencing; High throughput sequencing; Bioinformatics; NGS; next-generation sequencing; HTS; high-throughput sequencing; FDA; U.S. Food and Drug Administration; C